Results of OlympiA are practice changing in treatment of breast cancer

Adjuvant olaparib treatment significantly improves invasive disease-free survival in women with BRCA mutation and high-risk HER2-negative breast cancer. With a median follow-up of 2.5 years, olaparib-treated patients had a 42% reduction in the risk of developing invasive relapse compared to placebo.